Calico Life Sciences
Calico Life Sciences is dedicated to understanding the biology of aging and age-related diseases, collaborating with institutions like the Broad Institute and AbbVie to advance drug discovery and clinical research.
Company Overview
Calico Life Sciences focuses on understanding the biology of aging and age-related diseases. The company employs advanced computing and beyond state-of-the-art technologies to advance research questions and clinical studies. By harnessing advanced technologies and model systems, Calico aims to increase understanding of the biology that controls human aging.
Research Collaborations
Calico collaborates with the Broad Institute of MIT and Harvard on drug discovery programs and has a significant partnership with the pharmaceutical company AbbVie. These collaborations empower Calico's research and clinical development efforts, enabling the company to work on more than 20 early- and late-stage preclinical compounds in areas such as cancer, neurological diseases, and tissue homeostasis and repair.
Scientific Studies and Model Organisms
Calico's research efforts involve the study of various organisms, including yeast, C. elegans (worms), mice, and human cells and tissues. This diverse approach allows Calico to explore biological mechanisms across different species and improve the understanding of aging and age-related diseases.
Postdoctoral Fellowship Program
Calico offers a postdoctoral fellowship program that provides a four-year educational assignment for individuals who have recently completed their Ph.D. degrees. Postdoctoral fellows at Calico focus on independent projects and contribute to existing programs related to aging and age-related diseases. They receive regular feedback and guidance from mentors and participate in a formal annual review process to ensure progress and development.
ABBV-CLS-7262 Clinical Trials
Calico's investigational drug ABBV-CLS-7262 targets eIF2B, a key regulator of the integrated stress response (ISR). A 96-week open-label, single-arm clinical trial is currently underway to evaluate the safety, tolerability, and pharmacokinetics of ABBV-CLS-7262 in participants with Vanishing White Matter disease. The drug is also being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS) in two ongoing studies. ABBV-CLS-7262 is licensed from the University of California, San Francisco, based on technology from the lab of Peter Walter, Ph.D.